Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Mitotic activity and survival in advanced non-Hodgkin's lymphoma of unfavourable histology

Brandt, L. ; Johnson, A. LU ; Olsson, H. LU orcid and Åkerman, M. LU (1990) In European Journal of Cancer and Clinical Oncology 26(3). p.227-230
Abstract

The number of mitoses per high power field (mitotic index, MI) was assessed in 2 νm sections of lymph node biopsies from 58 adults with non-Hodgkin's lymphoma. All had diffuse nodal lymphomas of unfavourable histology and stage II-IV disease. The patients were treated with chemotherapy and followed for a minimum of 3 years or until death. None out of 29 patients with a MI ≥ 3.0 survived for 3 years after diagnosis whereas 13 out of 29 other patients with MI <3.0 became long-term survivors (P = 0.00002). Differences in age, sex or clinical stage between short- and long-term survivors were negligible. The initial chemotherapy regimens were not more intense for the long-term survivors. Twenty-nine patients were given an equivalent... (More)

The number of mitoses per high power field (mitotic index, MI) was assessed in 2 νm sections of lymph node biopsies from 58 adults with non-Hodgkin's lymphoma. All had diffuse nodal lymphomas of unfavourable histology and stage II-IV disease. The patients were treated with chemotherapy and followed for a minimum of 3 years or until death. None out of 29 patients with a MI ≥ 3.0 survived for 3 years after diagnosis whereas 13 out of 29 other patients with MI <3.0 became long-term survivors (P = 0.00002). Differences in age, sex or clinical stage between short- and long-term survivors were negligible. The initial chemotherapy regimens were not more intense for the long-term survivors. Twenty-nine patients were given an equivalent initial treatment with CHOP or CHOP plus methotrexate. The association between MIs and survival was evident also in this subgroup. The results indicate that survival is extremely poor for patients with advanced diffuse nodal lymphomas of unfavourable histology and a high mitotic count. It seems especially important to evaluate alternative chemotherapy regimens, suggested to be more effective than current programmes, in this subset of patients.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Cancer and Clinical Oncology
volume
26
issue
3
pages
227 - 230
publisher
Elsevier
external identifiers
  • scopus:0025332137
  • pmid:2141480
ISSN
0277-5379
DOI
10.1016/0277-5379(90)90216-G
language
English
LU publication?
yes
id
e73c65c5-2a8b-43c8-aa54-0ec18e3bce38
date added to LUP
2018-12-19 13:12:07
date last changed
2024-01-15 10:20:58
@article{e73c65c5-2a8b-43c8-aa54-0ec18e3bce38,
  abstract     = {{<p>The number of mitoses per high power field (mitotic index, MI) was assessed in 2 νm sections of lymph node biopsies from 58 adults with non-Hodgkin's lymphoma. All had diffuse nodal lymphomas of unfavourable histology and stage II-IV disease. The patients were treated with chemotherapy and followed for a minimum of 3 years or until death. None out of 29 patients with a MI ≥ 3.0 survived for 3 years after diagnosis whereas 13 out of 29 other patients with MI &lt;3.0 became long-term survivors (P = 0.00002). Differences in age, sex or clinical stage between short- and long-term survivors were negligible. The initial chemotherapy regimens were not more intense for the long-term survivors. Twenty-nine patients were given an equivalent initial treatment with CHOP or CHOP plus methotrexate. The association between MIs and survival was evident also in this subgroup. The results indicate that survival is extremely poor for patients with advanced diffuse nodal lymphomas of unfavourable histology and a high mitotic count. It seems especially important to evaluate alternative chemotherapy regimens, suggested to be more effective than current programmes, in this subset of patients.</p>}},
  author       = {{Brandt, L. and Johnson, A. and Olsson, H. and Åkerman, M.}},
  issn         = {{0277-5379}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{3}},
  pages        = {{227--230}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Cancer and Clinical Oncology}},
  title        = {{Mitotic activity and survival in advanced non-Hodgkin's lymphoma of unfavourable histology}},
  url          = {{http://dx.doi.org/10.1016/0277-5379(90)90216-G}},
  doi          = {{10.1016/0277-5379(90)90216-G}},
  volume       = {{26}},
  year         = {{1990}},
}